Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This pilot trial will be used to assess the activity, safety and feasibility of doublet
immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma
with high risk features. The hypothesis is that the combination of durvalumab/MEDI4736 and
tremelimumab (doublet immunotherapy) with platinum-based chemotherapy (gemcitabine and
cisplatin) will yield an objective of 52% and improve complete resection rates in
intrahepatic cholangiocarcinoma. This will facilitate margin negative resection and
ultimately reduce recurrence rates and improve survival. Carrying out this trial in the
neoadjuvant setting potentially allows improved overall survival and also provides an
opportunity for discovery of biomarkers that may predict response to therapy.